NCT03597919View on ClinicalTrials.gov

A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.

PHASE4CompletedINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

May 28, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

January 15, 2020

Conditions
Poliomyelitis
Interventions
BIOLOGICAL

Sabin IPV

We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.

Trial Locations (1)

Unknown

Shandong Center for Disease Control and Prevention, Jinan

All Listed Sponsors
collaborator

Shandong Province Centers for Disease Control and Prevention

OTHER

collaborator

World Health Organization

OTHER

lead

Centers for Disease Control and Prevention, China

OTHER_GOV

NCT03597919 - A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. | Biotech Hunter | Biotech Hunter